The Dana-Farber/Novartis Drug Discovery and Translational Research Program (DDTRP) is pleased to announce a competition for three-year Grants with funding to begin in July 2021. The Program integrates leading academic research and Novartis scientific
drug discovery and development efforts to advance better oncology therapeutics to improve patient outcomes.
Thus, while excellent science is required for funding, the prospect that a project might yield information useful in drug discovery and clinical application is also necessary. Novartis encourages participation from all Boston academic medical institutions
associated with the Dana-Farber/Harvard Cancer Center (DF/HCC — including BIDMC, BCH, BWH, DFCI, MGH, HMS, HSPH), whether or not the primary applicant is a DF/HCC member.
Please request the RFA to review the full details of this round's Grants, including application process, topics of interest, and eligibility criteria.
Grant Summaries Deadline: February 1, 2021
Sponsor Response to Grant Summaries: March 1, 2021
Completed IP/COI Review Deadline: March 31, 2021
Full Application Deadline: April 15, 2021
Award Notification: June 16, 2021
July 1, 2021
All Grant Summaries are to be submitted on the DDTRP online submission portal.
A template for the Grant Summary is available.
All program inquiries regarding the Grant Summary and application process should be directed to Sylvia Lin, DDTRP Program Administrator.
Register for Email Notifications
The Program is open to independent investigators at all institutions associated with DF/HCC, including BCH, BWH, BIDMC, DFCI, HMS, HSPH, MGH. Individual eligibility will be determined by whether your home institution accepts the terms of the Novartis
DDTRP Program Management Team
Steering Committee, Novartis
Steering Committee, Dana-Farber
Scientific Coordinator, Novartis
Scientific Coordinator, Dana-Farber
Sylvia Lin, Dana-Farber
Alliance Manager, Novartis
Alliance Manager, Dana-Farber